A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions
  • Acronyms GEMINI 1 ACS; GEMINI ACS 1
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 18 Mar 2017 Results published in the Internet Document-The Lancet.
    • 18 Mar 2017 According to a Janssen Pharmaceuticals media release, this trial is part of Janssen's EXPLORER clinical research program.
    • 18 Mar 2017 Results published in a Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top